Eli Lilly and Company
LLY
Below: live stock price for Eli Lilly and Company (LLY), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Eli Lilly and Company (LLY) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 50,000 people. Over the past year LLY traded between 793.82 and 1,292.65 USD. Trailing P/E sits near 42.2 on a market cap of about 1.12T USD. It currently yields 0.55% in dividends.
- Prev close
- $1,251.61
- Volume (24h)
- $3.02B
- Market cap
- $1.12T
- Currency
- USD
Score
58/ 100 · Mixed
- Value24
- Quality100
- Momentum70
- Growth77
- Risk60
- Dividend53
- Liquidity24
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 1,255.63 -0.11%
- +20 bars
- 1,253.71 -0.26%
- +60 bars
- 1,252.96 -0.32%
- +120 bars
- 1,252.93 -0.33%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0327 USD.
Interpretation
Composite signals look mixed. Strength: quality with weakness: balance-sheet liquidity. Price sits near the upper third of the recent range, trend is roughly flat.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value24/100
Value looks fragile — driven by P/E (42.2).
P/E:42.2P/B:33.08PEG:1.22 - Quality100/100
Quality looks strong — driven by ROE (102.29%).
ROE:102.29%ROA:20.36%Profit margin:33.53%Gross margin:83.40% - Momentum70/100
Momentum looks solid — driven by 52w change (55.39%).
52w change:55.39% - Growth77/100
Growth looks strong — driven by Revenue growth (47.70%).
Revenue growth:47.70%Earnings growth:26.20% - Risk60/100
Risk looks solid — driven by Debt / equity (162.07).
Beta:0.45Debt / equity:162.07Short interest:0.79% - Dividend53/100
Dividend looks mixed — driven by Payout ratio (21.69%).
Dividend yield:0.55%Payout ratio:21.69% - Liquidity24/100
Liquidity looks fragile — driven by Current ratio (1.36).
Current ratio:1.36Quick ratio:0.68
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 250 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 34.5%
- Max drawdown
- -23.3%
- Below period high
- -2.8%
- Best day
- +10.33%
- Worst day
- -7.79%
- Up days
- 51%
- Current streak
- 3 up
- Typical day swing
- 2.9%
- Volume vs average
- -14%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 1,292.65 high → 1,109.15 low · 60 bars
- ResistanceFib +161.8% extensionnot reached1,589.55 USD+26.45% from current
- ResistanceFib +100% extensionnot reached1,476.15 USD+17.43% from current
- ResistanceFib +61.8% extensionnot reached1,406.05 USD+11.86% from current
- ResistanceFib +27.2% extensionnot reached1,342.56 USD+6.80% from current
- Current1,257.03 USD
- SupportFib 23.6% retracementNearesttested 6×1,249.34 USD-0.61% from current
- SupportFib 38.2% retracementtested 9×1,222.55 USD-2.74% from current
- SupportFib 50% midpointtested 11×1,200.9 USD-4.47% from current
- SupportFib 61.8% retracementtested 23×1,179.25 USD-6.19% from current
- SupportFib 78.6% retracementtested 19×1,148.42 USD-8.64% from current
- SupportFib −27.2% extensionnot reached1,059.24 USD-15.73% from current
- SupportFib −61.8% extensionnot reached995.747 USD-20.79% from current
- SupportFib −100% extensionnot reached925.65 USD-26.36% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- $1,292.65
- 52w low
- $793.82
- 52w change
- 55.39%
- Day high
- $1,274.56
- Day low
- $1,251.25
- P/E (TTM)
- 42.2
- Forward P/E
- 26.64
- PEG
- 1.22
- Price / Book
- 33.08
- Beta (5Y)
- 0.45
- Enterprise value
- 1.17T
- EV / Revenue
- 14.64
- EV / EBITDA
- 27.97
- EPS (TTM)
- $29.79
- Forward EPS
- $47.19
- Dividend yield
- 0.55%
- Dividend rate
- $6.92
- Payout ratio
- 21.69%
- Revenue (TTM)
- 79.67B
- EBITDA
- 41.71B
- Free cash flow
- 11.07B
- Total cash
- 8.95B
- Total debt
- 54.91B
- Debt / Equity
- 162.07
- Current ratio
- 1.36
- Quick ratio
- 0.68
- Profit margin
- 33.53%
- Gross margin
- 83.40%
- Return on assets
- 20.36%
- Return on equity
- 102.29%
- Shares outstanding
- 891.36M
- Float
- 888.94M
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Analyst & Risk
- Beta (vs S&P 500)
- 0.45
- very stable
- 52-week change
- 55.39%
- Short % of float
- 0.79%
- Short ratio (days)
- 3.01
- Debt / Equity
- 162.07
- very high leverage
- Current ratio
- 1.36
- Quick ratio
- 0.68
- ROE
- 102.29%
- ROA
- 20.36%
- PEG ratio
- 1.22
- fair
- EV / Revenue
- 14.64
- EV / EBITDA
- 27.97
- Revenue growth
- 47.70%
- Earnings growth
- 26.20%
- EBITDA
- 41.71B
- Free cash flow
- 11.07B
- Total cash
- 8.95B
- Total debt
- 54.91B
- Insider holdings
- 0.16%
- Institutional
- 85.36%
Recent rating changes
- 2026-10-12RBC CapitalOutperform → Outperformreit
- 2026-10-08Cantor FitzgeraldOverweight → Overweightmain
- 2026-10-07Morgan StanleyOverweight → Overweightmain
- 2026-09-28JP MorganOverweight → Overweightmain
- 2026-09-22TD CowenBuy → Buyreit
- 2026-09-18GuggenheimBuy → Buymain
- 2026-09-10HSBCReduce → Reducemain
- 2026-08-07Truist SecuritiesBuy → Buymain
Financial documents
- Corporate Changes & Voting Matters8-K2026-08-05
- Annual report of employee stock purchase11-K2026-06-23
- Corporate Changes & Voting Matters8-K2026-05-20
- Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)SD2026-05-11
- Corporate Changes & Voting Matters8-K2026-05-07
- Corporate Changes & Voting Matters8-K2026-04-30
- Proxy StatementsDFAN14A2026-03-31
- Proxy StatementsDEF 14A2026-03-20
- Proxy StatementsPRE 14A2026-03-06
- Periodic Financial Reports10-K2026-02-12
- Corporate Changes & Voting Matters8-K2026-02-04
- Tender Offer/Acquisition ReportsSC TO-T/A2025-12-09
Recent news
- Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) CongressPR Newswire3h ago
- Is Novo Nordisk (CPSE:NOVO B) Cheap After Lillys EMA Win Raised GLP 1 Pressure?Simply Wall St.8h ago
- Is Novo Nordisk (CPSE:NOVO B) Facing A Bigger Threat In Europe?Simply Wall St.9h ago
- Can Eli Lilly’s (LLY) Growth Machine Keep Delivering?Insider Monkey11h ago
- European Union Regulators Recommend Approval For Eli Lilly Weight Loss PillTIKR12h ago
- The EU’s Drug Regulator Backed Eli Lilly’s Weight-Loss Pill. Here’s What Foundayo Has to Show on October 29TIKR1d ago
- What Was Eli Lilly Telling You Before Its Stock Ran?Trefis1d ago
- 3 Great Biotech Stocks To Watch In October 2026Simply Wall St.2d ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,431 USD-1.27%
- 7203.TToyota Motor Corporation3,075 USD-0.61%
- 9984.TSoftBank Group Corp.4,732 USD-4.29%
- 6758.TSony Group Corporation3,946 USD-0.33%
- 6861.TKeyence Corporation79,950 USD-1.00%
- NVDANVIDIA Corporation214.13 USD-1.43%
- AAPLApple Inc.343.46 USD+0.43%
- GOOGLAlphabet Inc.340.59 USD-2.47%
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.